Electromyographic biofeedback (EMG-BF) can be regarded as an adjuvant to pelvic floor muscle (PFM) training (PFMT) for the management of stress urinary incontinence (SUI). This meta-analysis aimed to compare the efficacy of PFMT with and without EMG-BF on the cure and improvement rate, PFM strength, urinary incontinence score, and quality of sexual life for the treatment of SUI or pelvic floor dysfunction (PFD). PubMed, Embase, the Cochrane Library, Web of Science, Wanfang, and CNKI were systematically searched for studies published up to January 2021. The outcomes were the cure and improvement rate, symptom-related score, pelvic floor muscle strength change, and sexual life quality. Twenty-one studies (comprising 1,967 patients with EMG-BF+PFMT and 1,898 with PFMT) were included. Compared with PFMT, EMG-BF+PFMT had benefits regarding the cure and improvement rate in SUI (OR 4.82, 95% CI 2.21 to 10.51, p < 0.001; I2 = 85.3%, p-heterogeneity < 0.001) and in PFD (OR 2.81, 95% CI 2.04 to 3.86, p < 0.001; I2 = 13.1%, p-heterogeneity = 0.331), and in quality of life using the I-QOL tool (SMD 1.47, 95% CI 0.69 to 2.26, p < 0.001; I2 = 90.1%, p-heterogeneity < 0.001), quality of sexual life using the FSFI tool (SMD 2.86, 95% CI 0.47 to 5.25, p = 0.019; I2 = 98.7%, p-heterogeneity < 0.001), urinary incontinence using the ICI-Q-SF tool (SMD -0.62, 95% CI -1.16 to -0.08, p = 0.024), PFM strength (SMD 1.72, 95% CI 1.08 to 2.35, p < 0.001; I2 = 91.4%, p-heterogeneity < 0.001), and urodynamics using Qmax (SMD 0.84, 95% CI 0.57 to 1.10, p < 0.001; I2 = 0%, p-heterogeneity = 0.420) and MUCP (SMD 1.54, 95% CI 0.66 to 2.43, p = 0.001; I2 = 81.8%, p-heterogeneity = 0.019). There was limited evidence of publication bias. PFMT combined with EMG-BF achieves better outcomes than PFMT alone in SUI or PFD management.

Full text (sometimes free) may be available at these link(s):      help

• PubMed Central
• DOI
• PubMed
• PDF locator
• publisher